Korea Research Institute of Chemical Technology

The Catholic University of Korea Industry-academic Cooperation Foundation

Yungjin Pharmaceuticals Co., Ltd.

Samsung Life Public Welfare Foundation

Woo Kyu Park

Heeyeong Cho

Hee-Jong Lim

Jae Yang Kong

Dae Young Jeong

Ge Hyeong Lee

Hyeon Young Kim

Seong Hwan Kim

Seung Won Choi

Chong Ock Lee

Do Hyun Nam

Young Sik Jung

Gildon Choi

Sung-Gyu Kim

Jung Hwan Choi

Ji Hye Choi

Su Jung Park

Yong Jun Chung

Chang Woo Lee

Jin Il Choi

Sae-Bom Yoon

Heung Kyoung Lee

Victor Sukbong Hong

Churl Min Seong

No Sang Park

Chul Soo Cho

Wan Uk Kim

Yoon Sung Jung

Eun Jin Han

Sunkyung Lee

Ho Jun Seol

The present invention relates to a pharmaceutical composition for preventing or treating autoimmune diseases or tumors, containing, as an active ingredient, a tricyclic compound represented by the following Chemical Formula 1 or a pharmaceutically acceptable salt thereof, and a health food composition for preventing or alleviating autoimmune diseases or tumors, containing the tricyclic compound as an active ingredient,

Tricyclic compound as IRAK4 inhibitor

The present invention relates to a heteroaryl derivative represented by Formula 1 

Heteroaryl derivative or pharmaceutically acceptable salt thereof, preparation method therefor, and pharmaceutical composition for preventing or treating diseases associated with PI3 kinases, containing same as active ingredient

The preset invention relates to a novel 8-oxoprotoberberine derivative or a pharmaceutically acceptable salt thereof, a preparation method thereof, and a pharmaceutical composition for preventing or treating diseases associated with the activity of NFAT5 containing the same as an active ingredient. The novel 8-oxoproteoberberine derivative or the pharmaceutically acceptable salt thereof according to the present invention can be useful in a pharmaceutical composition for preventing or treating diseases associated with the activity of NFAT5, particularly rheumatoid arthritis or inflammatory diseases, since it is ascertained that the derivative or a pharmaceutically acceptable salt thereof has remarkably increased oral absorption compared with known protoberberine due to an improvement in the properties thereof, and inhibits the activity of NFAT5 and the secretion of inflammatory cytokines and reduces the expression of NAFT5 in mice with rheumatoid arthritis by directly inhibiting the transcription of NFT5.

8-oxoprotoberberine derivative or pharmaceutically acceptable salt thereof, preparation method therefor and pharmaceutical composition for preventing or treating diseases associated with activity of NFAT5, containing same as active ingredient

The present invention relates to new quinoline derivatives of formula (1) or their pharmaceutically acceptable salts with caspase-3 inhibitory activity and their preparation methods, wherein Ris H; halogen; Calkyl; Calkoxy; Calkoxyalkyl; or Ccycloalkyl; Ris formula (a); &#x2014;CN; or formula (b); R is H; Caryl unsubstituted or substituted by halogen, Calkyl, Calkoxy or amino; 5&#x2013;15 membered heterocyclic group unsubstituted or substituted by halogen, Calkyl, Calkoxy or amino; or &#x2014;(CH)&#x2014;CHRR. The present invention relates to a pharmaceutical composition for treating caspase-associated diseases by inhibiting the activity of caspase-3 which comprises the compound of formula (1) or its pharmaceutically acceptable salt.

Quinoline derivatives as caspase-3 inhibitor, preparation for producing the same and pharmaceutical composition comprising the same

A class of quinolinic sulfide derivatives of formula I are potent and specific antagonists at the strychnine insensitive glycine bitding site on the NMDA receptor complex with an pharmacological advantageous profile. They may be useful in treatment or prevention of neuro-degenerative disorders. Particularly, the compounds included in the present invention are especially useful for minimizing damage of the central nervous system arising as a consequence of ischemic or hypoxic condition such as stroke, hypoglycemia, cerebral ischemia, cardiac arrest, and physical trauma. They are also useful in prevention of chronic neurodegenerative disorders including epilepsy, Alzheimer's disease, Huntington's disease and Parkinsonism. By virtue of their NMDA receptor antagonist properties, the present compounds may also use as anticonvulsant, analgesic, antidepressant, anxiolytic, and antischizophrenic agent. Formula I ##STR1## wherein R.sub.1, R.sub.2, R.sub.3, R.sub.4, and R are defined in specification.

Quinolinic sulfide derivatives acting as NMDA receptor antagonists and

Growing community of inventors

Chungcheongbuk-do, South Korea

Woo Kyu Park